In search of a small-molecule inhibitor for respiratory syncytial virus

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Respiratory syncytial virus has been an ongoing health problem for 50 years. Hospitalization rates due to virus-induced respiratory illness continue to be substantial for infants, small children, the elderly and the immunocompromised. The only currently available treatments are a broad-spectrum antiviral and two immunoprophylactic antibodies, all of which are reserved for high-risk patients. The combination of this limited therapeutic repertoire and the lack of a vaccine clearly demonstrates the need to continue the search for more efficacious and safe agents against respiratory syncytial virus. The following is a review on the current progress of that search.

Original languageEnglish (US)
Pages (from-to)625-639
Number of pages15
JournalExpert Review of Anti-Infective Therapy
Volume2
Issue number4
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Respiratory Syncytial Viruses
Antiviral Agents
Hospitalization
Vaccines
Viruses
Antibodies
Health
Therapeutics

Keywords

  • Antivirals
  • Entry/fusion
  • IMPDH
  • Inhibitor
  • Respiratory syncytial virus
  • Ribavirin
  • RSV
  • Small molecule

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

In search of a small-molecule inhibitor for respiratory syncytial virus. / Douglas, Janet.

In: Expert Review of Anti-Infective Therapy, Vol. 2, No. 4, 08.2004, p. 625-639.

Research output: Contribution to journalArticle

@article{f4be2330890d4279af179eae8ec5c7d0,
title = "In search of a small-molecule inhibitor for respiratory syncytial virus",
abstract = "Respiratory syncytial virus has been an ongoing health problem for 50 years. Hospitalization rates due to virus-induced respiratory illness continue to be substantial for infants, small children, the elderly and the immunocompromised. The only currently available treatments are a broad-spectrum antiviral and two immunoprophylactic antibodies, all of which are reserved for high-risk patients. The combination of this limited therapeutic repertoire and the lack of a vaccine clearly demonstrates the need to continue the search for more efficacious and safe agents against respiratory syncytial virus. The following is a review on the current progress of that search.",
keywords = "Antivirals, Entry/fusion, IMPDH, Inhibitor, Respiratory syncytial virus, Ribavirin, RSV, Small molecule",
author = "Janet Douglas",
year = "2004",
month = "8",
language = "English (US)",
volume = "2",
pages = "625--639",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - In search of a small-molecule inhibitor for respiratory syncytial virus

AU - Douglas, Janet

PY - 2004/8

Y1 - 2004/8

N2 - Respiratory syncytial virus has been an ongoing health problem for 50 years. Hospitalization rates due to virus-induced respiratory illness continue to be substantial for infants, small children, the elderly and the immunocompromised. The only currently available treatments are a broad-spectrum antiviral and two immunoprophylactic antibodies, all of which are reserved for high-risk patients. The combination of this limited therapeutic repertoire and the lack of a vaccine clearly demonstrates the need to continue the search for more efficacious and safe agents against respiratory syncytial virus. The following is a review on the current progress of that search.

AB - Respiratory syncytial virus has been an ongoing health problem for 50 years. Hospitalization rates due to virus-induced respiratory illness continue to be substantial for infants, small children, the elderly and the immunocompromised. The only currently available treatments are a broad-spectrum antiviral and two immunoprophylactic antibodies, all of which are reserved for high-risk patients. The combination of this limited therapeutic repertoire and the lack of a vaccine clearly demonstrates the need to continue the search for more efficacious and safe agents against respiratory syncytial virus. The following is a review on the current progress of that search.

KW - Antivirals

KW - Entry/fusion

KW - IMPDH

KW - Inhibitor

KW - Respiratory syncytial virus

KW - Ribavirin

KW - RSV

KW - Small molecule

UR - http://www.scopus.com/inward/record.url?scp=4444376950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444376950&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 625

EP - 639

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 4

ER -